Phase I study of the combination of alpha-2 interferon and cisplatinum.
Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 10(6) U/m2 alpha interferon was given three times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 10(6) U/m2 of alpha-2 interferon three times weekly and 25 mg/m2 of cisplatinum once weekly.
Walsh
C
C
Kaplan Cancer Center, New York University Medical Center, New York 10016.
Speyer
J L
JL
Wernz
J
J
Hochster
H
H
Grossberg
H
H
Chachoua
A
A
Molinaro
P
P
Meyers
M
M
Blum
R H
RH
D002945:Cisplatin / Q000008:administration & dosage*; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002945:Cisplatin